Delving into the Latest Updates on Dasatinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

anh. dasatinib, Anhydrous dasatinib, BMS dasatinib

+ [26]

Target

EphA2 x FYN x LCK x PDGFRβ x SRC x YES1 x c-Kit

Action

antagonists, inhibitors

Mechanism

EphA2 antagonists(Ephrin type-A receptor 2 antagonists), FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), LCK inhibitors(Tyrosine-protein kinase LCK inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [6]

Active Indication

Aggressive-Phase Chronic Myelocytic LeukemiaPhiladelphia chromosome-positive chronic myeloid leukemia in chronic phasePhiladelphia chromosome positive chronic myelogenous leukemia+ [12]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAdenocarcinoma of prostate+ [81]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Accord Healthcare SL

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIG

+ [11]

Inactive Organization

Otsuka Pharmaceutical Development & Commercialization, Inc.

Celgene Corp.

OSI Pharmaceuticals, Inc.

+ [2]

License Organization

Eversana Life Science Services LLC

Handa Pharmaceuticals, Inc.

Cycle Pharmaceuticals Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (28 Jun 2006),

Acute Lymphoblastic LeukemiaBlast Phase Chronic Granulocytic LeukemiaChronic phase chronic myeloid leukemia

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H28ClN7O3S

InChIKeyXHXFZZNHDVTMLI-UHFFFAOYSA-N

CAS Registry863127-77-9

This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.

Start Date01 Jan 2027

Sponsor / Collaborator

Friedrich Schiller University of Jena

NCT07269470

/ RecruitingPhase 2IIT

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Start Date13 Jul 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

CTRI/2026/06/112499

/ RecruitingPhase 2IIT

Comparison of Dasatinib plus DPP IV inhibitor Vildagliptin versus Dasatinib monotherapy in reduction of peripheral blood leukemic stem cells in chronic myeloid leukemia: a randomized, exploratory pilot study

Start Date22 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Dasatinib

Login to view more data

100 Translational Medicine associated with Dasatinib

Login to view more data

100 Patents (Medical) associated with Dasatinib

Login to view more data

5,947

Literatures (Medical) associated with Dasatinib

01 May 2027·Value in Health Regional Issues

Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia

Article

Author: Ospina, Juan Alejandro ; Prieto, Natalia ; Lasalvia, Pieralessandro ; Jaramillo, Paola ; Ceballos, Mateo ; Abello, Virginia ; Arias, Sara

OBJECTIVES:

To assess the cost-effectiveness of asciminib in adult patients with chronic-phase chronic myeloid leukemia who have been treated with 2 or more tyrosine kinase inhibitors, from a third-party payer perspective in Colombia.

METHODS:

A nonhomogeneous partitioned survival model was developed using ASCEMBL trial and matching-adjusted indirect comparisons. Outcomes included overall survival, progression-free survival, and safety. Overall survival was modeled using exponential functions based on 6-month major molecular response rates. Quality-adjusted life-years (QALYs) were estimated using phase-specific utilities. Direct medical costs were obtained from national public databases (2024-2025) and expressed in 2025 USD (USD 1 = COP 4053). A 30-year time horizon was applied. Base case compared asciminib with bosutinib and ponatinib. Scenario analyses included nilotinib and dasatinib because they are rarely used in third line in Colombia. Sensitivity analyses explored ponatinib dose deescalation, generic drug pricing, asciminib price thresholds, relative dose intensity, and alternative overall survival assumptions. Probabilistic sensitivity analyses were performed.

RESULTS:

Asciminib was dominant compared with bosutinib and ponatinib, yielding more QALYs (0.41 and 0.20) and lower costs (-USD 47 334 and -USD 88 554). Scenario analyses including nilotinib and dasatinib favored asciminib, with higher QALYs (0.32 and 0.25) and lower costs (-USD 43 785 and -USD 6400). Results remained robust across analyses, including ponatinib dose deescalation, generic pricing, relative dose intensity, and alternative overall survival assumptions.

CONCLUSIONS:

Asciminib was a dominant treatment option for patients with chronic-phase chronic myeloid leukemia who have been treated with 2 or more tyrosine kinase inhibitors, offering clinical and economic advantages over other pharmacological treatments.

01 Apr 2027·DEN open

Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post‐Biopsy Bleeding

Article

Author: Yamane, Hiromichi ; Kosaka, Yoko ; Nakanishi, Hidekazu ; Takigawa, Nagio

ABSTRACT:

A 76‐year‐old man was referred to our hospital for evaluation of anemia. Although he was elderly (≥75 years), no apparent risk factors for bleeding during endoscopic biopsy, such as renal dysfunction or anticoagulant therapy, were identified. Upper gastrointestinal endoscopy revealed extensive atrophic gastric mucosa extending from the antrum to the gastric body. A biopsy was obtained from the atrophic mucosa in the antrum for histopathological evaluation after confirming a low risk of bleeding. Eight days after the initial endoscopy, the patient was hospitalized and started on nilotinib for chronic myeloid leukemia, which had been subsequently diagnosed. Gastrointestinal bleeding occurred 5 h after the initiation of nilotinib. Emergency endoscopy revealed a reddish polypoid lesion with active bleeding at the previous biopsy site. Endoscopic polypectomy was performed, and hemostasis was achieved. Delayed gastric bleeding after upper gastrointestinal endoscopic biopsy alone is extremely rare. Current guidelines in Japan state that tissue biopsy is acceptable when clinically indicated, even in patients receiving anticoagulant or antiplatelet therapy. Although no definitive cause was identified, myeloproliferative disorders are associated with bleeding tendencies due to coagulation abnormalities and drug‐induced bleeding related to tyrosine kinase inhibitors such as dasatinib and nilotinib. These factors may have contributed to the delayed bleeding in this case. This case highlights the importance of careful follow‐up after endoscopic biopsy in patients with underlying myeloproliferative disorders.Trial Registration : N/A.

01 Dec 2026·BIOMATERIALS

Piezocatalytic nanotransducers rewire tumor immunometabolism via in situ peroxynitrite generation

Article

Author: Liu, Yingdan ; Fu, Yang ; Xue, Weili ; Gao, Dawei ; Yan, Xiyun ; Zhang, Jinhui ; He, Yuchu ; Yan, Junxin ; Ye, Kun ; Dong, Zhechen ; Zhang, Xuwu ; Tu, Wenkang

The dense extracellular matrix (ECM) and stromal cells in breast cancer constitute a formidable physical and immunosuppressive barrier that facilitates immune evasion and tumor progression. Within this desmoplastic microenvironment, cancer-associated fibroblasts (CAFs) overexpress indoleamine 2,3-dioxygenase-1 (IDO-1), an enzyme that activates the tryptophan-kynurenine metabolic pathway to induce T cell exhaustion and immune tolerance. Consequently, modulating tryptophan metabolism in CAFs represents a promising strategy to potentiate antitumor immunotherapy. Herein, we develop a CAF-targeted nanomedicine system based on dasatinib-loaded Nb₂GeTe₄ (NGT) nanosheets for ultrasound-mediated immunometabolic modulation. Under low-intensity ultrasound, NGT exhibits efficient piezocatalytic charge separation, efficiently separating electron-hole pairs to trigger the generation of superoxide anions (·O₂^-). These reactive species rapidly react with intracellular nitric oxide to form peroxynitrite (ONOO^-), which induces site-specific tyrosine nitration of IDO-1. This process irreversibly inactivates IDO-1, thereby disrupting the tryptophan-kynurenine immunosuppressive axis. Simultaneously, the controlled release of dasatinib inhibits CAF-mediated fibrosis, dismantling the stromal barrier, reducing tumor stiffness and facilitating the infiltration of cytotoxic T lymphocytes. This study establishes a precise piezocatalysis-driven strategy for reprogramming the tumor microenvironment in desmoplastic malignancies, providing a promising avenue for the development of two-dimensional nanomaterials in cancer immunotherapy.

144

News (Medical) associated with Dasatinib

06 Oct 2026

·www.prnewswire.com

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML). United States Adopted Names (USAN) Council has adopted relcobatinib as the nonproprietary name for ELVN-001. Relcobatinib is an investigational, potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, the oncogenic driver of CML. "We are pleased to have reached alignment with the FDA on the design of the ENABLE-2 pivotal Phase 3 trial, providing a clear path to initiate the trial before year-end," said Helen Collins, M.D., Chief Medical Officer of Enliven. "ENABLE-2 is designed to directly compare relcobatinib to the second-generation TKIs and evaluate its potential to be the best-in-class ATP-competitive inhibitor for patients with CML. We are encouraged by the enthusiasm from physicians and the broader CML community as we prepare to initiate the trial." ENABLE-2 Phase 3 Trial Design: A 2L+ Pivotal Trial for Patients with CML ENABLE-2 is a planned randomized 2L+ phase 3 trial expected to enroll approximately 450 adults with CML previously treated with one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib 80 mg once daily or an investigator-selected second-generation TKI (dasatinib, nilotinib, or bosutinib). The primary endpoint is major molecular response (MMR) at Week 24, with the key secondary endpoint of MMR at Week 96. With approximately 450 patients, the trial is designed such that an improvement in MMR rate of at least 10 percentage points over the control arm would be sufficient to demonstrate statistical superiority. We believe this difference would represent a clinically meaningful improvement over currently available second-generation TKIs. The Company remains on track to initiate ENABLE-2 before year-end 2026. About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit and connect with us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of Enliven's management, as well as assumptions made by, and information currently available to, Enliven's management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential of, and plans regarding, market opportunities, and expectations regarding relcobatinib (ELVN-001); statements regarding the potential profile, activity, selectivity, safety, tolerability, efficacy, differentiated attributes, therapeutic benefit and potential best-in-class or complementary profile of relcobatinib to allosteric inhibitors; the interpretation of data from the ongoing ENABLE trial, including MMR rate, safety and tolerability data; comparisons to historical or precedent clinical trial results; the timing, content and availability of additional clinical data and presentation materials; the continued conduct, design, objectives, endpoints, dose selection and future clinical evaluation of relcobatinib, including the planned ENABLE-2 Phase 3 trial, the statistical power, sample size assumptions and expected treatment effect sizes for ENABLE-2 and the belief that such treatment benefit would be clinically meaningful, the potential timing of initiation of ENABLE-2, the potential timing and outcome of further FDA discussions and the finalization of additional Phase 3 trial design details; and statements by Enliven's Chief Medical Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation the limited operating history of Enliven; the potential for interim, topline and preliminary results from Enliven's clinical trials to materially change as additional patient data become available or following more comprehensive review; the potential for results from the ongoing or any future clinical trial of relcobatinib to differ from the results of earlier trials of relcobatinib; relcobatinib failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; risks associated with unexpected events during the remainder of the ENABLE trial including serious adverse events, toxicities, dose reductions, discontinuations or other undesirable side effects; delays or difficulties in recruiting, enrolling or maintaining patients in relcobatinib clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to present additional data, to initiate ENABLE-2 or to advance relcobatinib through clinical development; regulatory authorities disagreeing with Enliven's clinical trial design, dose selection, endpoints or interpretation of data, or requiring additional studies or diagnostics; the risk that statistical assumptions underlying the ENABLE-2 trial design may not hold, including assumptions regarding treatment effect sizes, comparator arm performance and statistical power; lack of reliability of cross-trial comparisons because the referenced data are derived from different clinical trials at different points in time, with differences in trial design and patient populations, and results may differ in head-to-head studies; developments relating to Enliven's competitors and industry which may affect the development or potential market opportunity for relcobatinib; and the potential inability of Enliven to obtain regulatory approval for, or ultimately commercialize or license, relcobatinib or other product candidates; Enliven's limited resources; Enliven's limited experience as a company in designing and conducting clinical trials; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geopolitical developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q filed with the SEC and in Enliven's future SEC filings. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. SOURCE Enliven Therapeutics, Inc. 21% more press release views with Request a Demo

Phase 3Phase 2

14 Sep 2026

·www.sciencedaily.com

Scientists supercharge immune cells to destroy cancer more effectively

Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, briefly suppressing the cells with a drug before use made them even more effective later. The approach could help create safer, stronger next-gen cancer treatments.Researchers in Brazil are advancing a promising form of cancer immunotherapy by making natural killer (NK) cells more powerful and precise. In a recent study, scientists at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) used the NK-92 cell line to test new designs of chimeric antigen receptors (CARs). These engineered receptors included specific costimulatory components, such as 2B4 and DAP12, that help activate the cells. The findings showed that these additions made the cells "ready to attack," significantly improving their ability to destroy tumor cells. The study was published in Frontiers in Immunology. CAR-based therapies have already transformed cancer treatment, particularly for blood-related cancers. While CAR-T cells are well studied, scientists are still working to understand how to optimize CAR-NK cells. One key challenge is identifying which internal signaling mechanisms allow these cells to perform at their best. The new research addresses this gap by focusing on how specific signaling domains influence NK cell activity. By incorporating 2B4 and DAP12 into the CAR design, the researchers were able to enhance the cells' activation state, making them more effective at targeting tumors. Combining activation signals with drug control The team also explored a strategy to fine-tune the cells using a temporary drug-based approach. They tested dasatinib, a drug that can briefly suppress cell activity, to see how controlled pauses might affect performance. Their results suggest that combining optimized activation signals with reversible pharmacological control can improve both the strength and efficiency of CAR-NK therapies. This approach may help researchers design more advanced and controllable cell-based cancer treatments in the future. Stronger tumor control in preclinical models According to the Ribeirão Preto Blood Center Press Office, experiments in animal models showed encouraging results. CAR-NK cells engineered with 2B4-DAP12 and pretreated with dasatinib were better at controlling tumor growth compared to more traditional versions of the therapy. Research collaboration and institutional support The Center for Cell-Based Therapy (CTC) is one of the Research, Innovation, and Dissemination Centers (RIDCs) supported by FAPESP. It operates within the Ribeirão Preto Blood Center and is affiliated with the general and teaching hospital ("Hospital das Clínicas") of the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP). Together, these findings point toward a new generation of CAR-NK therapies that could offer stronger, more adaptable ways to fight cancer.

11 Sep 2026

·www.fiercepharma.com

After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis

Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third time. On Friday, the U.S. and Taiwan-headquartered company announced final FDA approval for its Omcazio capsules, a laurylsulfate salt formulation of Exelixis’ cancer med Cabometyx that uses cabozantinib, the same tyrosine kinase inhibitor active ingredient. The novel formulation of Exelixis’ patent-protected med was devised by the company’s Handa Oncology subsidiary and shifts a prior tentative approval into a formal green light, clearing the way for the drug to be marketed in the United States. Omcazio now joins two other branded reformulated medicines in Handa’s portfolio, Phyrago, a modified version of Bristol Myers Squibb’s oncology medicine Sprycel (dasatinib) that can be used alongside proton pump inhibitors and H2 receptor antagonists, and Tascenso ODT, an orally disintegrating tablet formulation of Novartis’ relapsing multiple sclerosis therapy Gilenya (fingolimod). Both of those products are being commercialized in the U.S. under licensing agreements with Cycle Pharmaceuticals. As for Omcazio, Handa said Friday that it plans to provide additional information on the drug’s U.S. commercial availability in a forthcoming announcement. The capsule’s key advantage, according to a statement from Handa CEO Bill Liu, is that it can be taken with or without food, which he said gives both doctors and patients “added flexibility in treatment.” The medicine can be used in adults with advanced renal cell carcinoma and as a first-line treatment in those patients in combination with BMS’ Opdivo, as well as in hepatocellular carcinoma patients previously treated with Bayer’s Nexavar and in adults and children 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors. Meanwhile, the 60-, 40- and 20-mg once-a-day doses of Cabometyx correspond to 34.5-, 23- and 11.5-mg daily doses of Omcazio, respectively, Handa noted. Cabometyx, which won its first approval more than a decade ago, is among the most commonly used oral targeted therapies in cancer treatment, per Handa. Last year, Exelixis reported a 17% sales bump for the medicine to $2.11 billion in the U.S. As for what Handa’s nod means for Exelixis, analysts at William Blair wrote to clients Friday that they don’t view the full approval of Omcazio as a threat. They cited the apparent gap between approval and commercial availability and further asserted that they believe Handa’s drug is “not equivalent to Cabometyx.” Omcazio was approved using bioavailability and bioequivalence data via the FDA’s 505(b)(2) pathway, the William Blair team pointed out. This pathway enables developers to rely in part on existing data supporting a previously approved drug, and is often used when a company is developing a new formulation or novel combination of an already-approved medicine. Nevertheless, Omcazio’s labeling specifically states that the drug is not substitutable on a milligram-to-milligram basis with other cabozantinib products. The William Blair analysts said they therefore believe Handa will “likely have to build a sales force to fully commercialize Omcazio,” adding that the lack of data also leads them to suspect “minimal” uptake of Omcazio in the U.S. The reformulation game has been picking up traction of late, as multiple developers look to retool versions of already-approved medicines in hopes of delivering a new, patent-protected product that fills some lingering unmet need. One prominent example is Veradermics, the buzzy hair-loss biotech that has continued to generate positive data —and investor excitement—around its lead candidate VDPHL01, which is an extended-release oral formulation of minoxidil. Minoxidil is likely better known by most as the topical hair loss treatment Rogaine, first approved in 1988. Meanwhile, an oral version of the drug was approved in the late 1970s as a blood pressure medicine, but it has not been approved in that format for hair loss.

Drug ApprovalLicense out/in

100 Deals associated with Dasatinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06414	Dasatinib	L01XE06	DB01254

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Aggressive-Phase Chronic Myelocytic Leukemia	European Union	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Iceland	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Liechtenstein	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Norway	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	European Union	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Iceland	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Liechtenstein	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Norway	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome positive chronic myelogenous leukemia	European Union	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Iceland	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Norway	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	European Union	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Iceland	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Norway	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Acute Lymphoblastic Leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006
Blast Phase Chronic Granulocytic Leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006
Chronic phase chronic myeloid leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Myelogenous Leukemia	NDA/BLA	United States	Xspray Pharma AB	18 Nov 2021
Castration-Resistant Prostatic Cancer	Phase 3	United States	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Argentina	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Australia	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Brazil	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Canada	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Czechia	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Finland	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	France	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Germany	Bristol Myers Squibb Co.	01 Oct 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IMS2026	Not Applicable	Trochlear Nerve Diseases	8	DasatinibIVIgtinib + DasatinibIVIgicosteroids + DasatinibIVIg	injdqscyvu(gohgkgxpma) = One patient developed a facial rash, which was the only adverse event directly attributed to dasatinib administration ljpryyxgty (wgdkexgscf )	Positive	23 Sep 2026
NCT06940297 (DART, IMS2026)	Phase 2	Refractory Multiple Myeloma	6	Dasatinib and Quercetin+CAR-T therapy	vhmzqptuvd(wjazfhkmeh) = phuvpzjgdw yvtwdfjeij (ystqmdatgj ) View more	Positive	23 Sep 2026
ASCO_Breakthrough2026	Not Applicable	Chronic phase chronic myeloid leukemia	118	Dasatinib	wryebfkvrp(vrmmmesamx) = wuebpipyjn dzcugrafls (ykxqaqewio ) View more	Positive	25 Jun 2026
ASCO_Breakthrough2026	Not Applicable	Chronic phase chronic myeloid leukemia	118	Nilotinib	wryebfkvrp(vrmmmesamx) = xvnkojgnsu dzcugrafls (ykxqaqewio ) View more	Positive	25 Jun 2026
EHA2026	Not Applicable	Chronic Myelogenous Leukemia	84	Dasatinib	fzjpmwaaxy(njmmtuvyza) = yqtmkjzcrg ulahecashk (buqcgvppag ) View more	Positive	12 May 2026
EHA2026	Not Applicable	-	42	Imatinib	pfsldtviwz(glssudidey) = TKI-related adverse events led to therapy modification in 28.5% fkucwrzrfp (pdhwkpvjfb )	Positive	12 May 2026
EHA2026	Not Applicable	Chronic phase chronic myeloid leukemia First line	103	Dasatinib 100 mg once daily	xidpilwdhr(bsgqhtbtiy) = szmhonapzc voauxmpqlp (qacsnqngot ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Chronic phase chronic myeloid leukemia First line	103	Dasatinib 50 mg once daily	xidpilwdhr(bsgqhtbtiy) = jeudswouna voauxmpqlp (qacsnqngot ) View more	Positive	12 May 2026
EHA2026	Not Applicable	BCR::ABL1 rearrangement	5	hyperCVAD+dasatinib	xqwdkqowjn(pacryplcsc) = xvsjssrytq dzbavxtbyr (pcvozooclh ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Chronic phase chronic myeloid leukemia	57	imatinib	ravjfhiuxc(bpxpkxxswc) = drtpoouhaj fiowcquqzl (fqlminccgk ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Chronic phase chronic myeloid leukemia	57	nilotinib	ravjfhiuxc(bpxpkxxswc) = rtgmdspead fiowcquqzl (fqlminccgk )	Positive	12 May 2026
EHA2026	Not Applicable	Philadelphia chromosome positive chronic myelogenous leukemia	16	Decitabine + Dasatinib	lajrafrsrm(yqixdzxpsh) = thrombocytopenia (50%), neutropenia (38%), anemia (38%), & febrile neutropenia (31%). ujravkigza (derykskgxt ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Chronic Myelogenous Leukemia First line	58	Dasatinib 50 mg/day	hpurtqwpaz(yvgssnhlfm) = imnteugjuq fhywsbfdaj (clulkwkrrm ) View more	Positive	12 May 2026